Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
Jerusalem, Guy ; Université de Liège - ULiège > Oncologie médicale
Fasolo, Angelica
Dieras, Véronique
Cardoso, Fatima
Bergh, Jonas
Vittori, Luc
Zhang, Yufen
Massacesi, Cristian
Sahmoud, Tarek
Gianni, Luca
Language :
English
Title :
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 1:CAS:528:DC%2BD3MXisVGktrc%3D 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
A Gschwind OM Fischer A Ullrich 2004 The discovery of receptor tyrosine kinases: targets for cancer therapy Nat Rev Cancer 4 361 370 1:CAS:528:DC%2BD2cXjsFSlu7g%3D 10.1038/nrc1360 15122207 (Pubitemid 38579482)
L Rydén G Landberg O Stål, et al. 2008 HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information Breast Cancer Res Treat 109 351 357 10.1007/s10549-007-9660-2 17636399 (Pubitemid 351644858)
NCCN Clinical Practice Guidelines in Oncology™. Breast Cancer (Version 1.2010). National Comprehensive Cancer Network, Inc. http://www.nccn.org
M Marty F Cognetti D Maraninchi, et al. 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265 4274 1:CAS:528:DC%2BD2MXms12gs70%3D 10.1200/JCO.2005.04.173 15911866 (Pubitemid 46207001)
American Cancer Society: Breast Cancer Facts & Figures 2007-2008. http://www.cancer.org/acs/groups/content/@nho/documents/document/bcfffinalpdf. pdf. Accessed 30 Sept 2010
R Nahta FJ Esteva 2003 HER-2-targeted therapy: lessons learned and future directions Clin Cancer Res 9 5078 5084 1:CAS:528:DC%2BD3sXovVOgtb4%3D 14613984
G von Minckwitz A du Bois M Schmidt, et al. 2009 Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study J Clin Oncol 27 1999 2006 10.1200/JCO.2008.19.6618
CE Geyer J Forster D Lindquist, et al. 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D 10.1056/NEJMoa064320 17192538 (Pubitemid 46021510)
Y Nagata KH Lan X Zhou, et al. 2004 PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 117 127 1:CAS:528:DC%2BD2cXns1arsr8%3D 10.1016/j.ccr.2004.06.022 15324695 (Pubitemid 39485684)
K Berns HM Horlings BT Hennessy, et al. 2007 A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 395 402 1:CAS:528:DC%2BD2sXht1ais7zL 10.1016/j.ccr.2007.08.030 17936563 (Pubitemid 47539306)
SL Ellard M Clemons KA Gelmon, et al. 2009 Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163 J Clin Oncol 27 4536 4541 1:CAS:528:DC%2BD1MXhtlCns77K 10.1200/JCO.2008.21.3033 19687332
A Awada F Cardoso C Fontaine, et al. 2008 The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics Eur J Cancer 44 84 91 1:CAS:528:DC%2BD2sXhsVOrurjK 10.1016/j.ejca.2007.10.003 18039566 (Pubitemid 350256937)
J Baselga V Semiglazov P van Dam, et al. 2009 Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer J Clin Oncol 27 2630 2637 1:CAS:528:DC%2BD1MXnslWit7s%3D 10.1200/JCO.2008.18.8391 19380449
J Tabernero F Rojo E Calvo, et al. 2008 Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors J Clin Oncol 26 1603 1610 1:CAS:528:DC%2BD1cXltlWiu7c%3D 10.1200/JCO.2007.14.5482 18332469
Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol. 2010 Oct 25. [Epub ahead of print]
A Chan 2007 A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer Ann Oncol 18 1152 1158 1:STN:280:DC%2BD2svls1Snug%3D%3D 10.1093/annonc/mdl476 17264064 (Pubitemid 47244359)
E De Maio C Pacilio A Gravina, et al. 2007 Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial BMC Cancer 7 50 10.1186/1471-2407-7-50 17374151 (Pubitemid 46502377)
G Schilling M Bruweleit N Harbeck, et al. 2009 Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy) Investig New Drugs 27 166 172 1:CAS:528:DC%2BD1MXitVOmtb8%3D 10.1007/s10637-008-9166-8
N Tokudome Y Ito K Hatake, et al. 2008 Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan Anticancer Drugs 19 753 759 1:CAS:528:DC%2BD1cXnvFehsr8%3D 10.1097/CAD.0b013e328302eb15 18594220
V Di Lauro A Murrone E Bidoli, et al. 2008 Trastuzumab and vinorelbine as highly effective and safe therapy for HER-2-overexpressing metastatic breast cancer. A single institution experience Tumori 94 464 468 1:CAS:528: DC%2BD1cXht1aqtLjJ 18822679
M Andersson E Lidbrink E Wist, et al. 2010 Similar outcome in a randomized phase III trial comparing docetaxel versus vinorelbine both combined with trastuzumab as first line treatment for metastatic or locally advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer Eur J Cancer 8 55 Abstract 8N
B Neuenschwander M Branson T Gsponer 2008 Critical aspects of the Bayesian approach to phase I cancer trials Stat Med 27 2439 10.1002/sim.3230 (Pubitemid 351802902)
Y Cheung R Chappell 2000 Sequential designs for phase I clinical trials with late-onset toxicities Biometrics 56 1177 1182 1:STN:280: DC%2BD3M7it1Cmuw%3D%3D 10.1111/j.0006-341X.2000.01177.x 11129476
National Cancer Institute (2006) Common Terminology Criteria for Adverse Events (CTCAE) v3.0. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf. Accessed 30 Sept 2010
CC Jaffe 2004 Measures of response: RECIST, WHO, and new alternatives Nat Rev Cancer 4 335 348 10.1038/nrc1362
C Tanaka T O'Reilly JM Kovarik, et al. 2008 Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data J Clin Oncol 26 1596 1602 1:CAS:528:DC%2BD1cXltlWiu7Y%3D 18332467
HA Lane JM Wood PMJ McSheehy, et al. 2009 mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor Clin Cancer Res 15 1612 1622 1:CAS:528: DC%2BD1MXisVWrsr0%3D 10.1158/1078-0432.CCR-08-2057 19223496
FJ Dumont MJ Staruch SL Koprak, et al. 1990 Distinct mechanisms of suppression of mustine T cell activation by the related macrolides FK-506 and rapamycin J Immunol 144 251 258 1:CAS:528:DyaK3cXptFCgsA%3D%3D 1688572
BD Manning 2004 Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis J Cell Biol 167 399 403 1:CAS:528: DC%2BD2cXpvVCgu7k%3D 10.1083/jcb.200408161 15533996 (Pubitemid 39489047)
R Nahta J Esteva 2006 HER2 therapy: molecular mechanisms of trastuzumab resistance Breast Cancer Res 8 215 10.1186/bcr1612 17096862 (Pubitemid 44804004)
Lindström L, Howell S, Åström G et al (2010) Controversies in the management of metastatic breast cancer: biologic evaluation of breast cancer: should metastases be biopsied? American Society of Clinical Oncology (ASCO) Educational Book. American Society of Clinical Oncology (ASCO), Alexandria
HJ Burstein I Kuter SM Campos, et al. 2001 Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer J Clin Oncol 19 2722 2730 1:CAS:528:DC%2BD3MXkt1Omu7k%3D 11352965
HJ Burstein LN Harris PK Marcom, et al. 2003 Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm J Clin Oncol 21 2889 2895 1:CAS:528:DC%2BD2cXpsVKjtro%3D 10.1200/JCO.2003.02.018 12885806 (Pubitemid 46621838)
Motzer RJ, Escudier B, Oudard S, The RECORD-1 Study Group et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256-4265
HJ Burstein A Keshaviah AD Baron, et al. 2007 Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study Cancer 110 965 972 1:CAS:528:DC%2BD2sXhtVChs7fM 10.1002/cncr.22885 17614302 (Pubitemid 47312860)
